Shanghai Fosun Long March Medical Science Co, signed a nonbinding Memorandum of Understanding with VolitionRx, an international company headquartered in Belgium, to bring Volition’s Nu.QTM diagnostic platform to China. The two companies expect to conduct three clinical studies in China for colorectal cancer, lung cancer and ovarian cancer diagnostics. Volition says it develops easy to use, cost-effective blood tests to diagnose various cancers and other diseases. Fosun Long March is the in vitro diagnostic subsidiary of Fosun Pharma.
Source: China Biotoday
